Serina Therapeutics Inc [SER] stock prices are down -0.18% to $5.64 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SER shares have gain 7.94% over the last week, with a monthly amount glided 4.44%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Serina Therapeutics Inc [AMEX: SER] stock has seen the most recent analyst activity on July 14, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $15.
The stock price of Serina Therapeutics Inc [SER] has been fluctuating between $3.81 and $10.28 over the past year. Serina Therapeutics Inc [AMEX: SER] shares were valued at $5.64 at the most recent close of the market.
Analyzing the SER fundamentals
The Serina Therapeutics Inc [AMEX:SER] reported sales of 0.13M for trailing twelve months, representing a surge of 2500.00%. Gross Profit Margin for this corporation currently stands at -0.99% with Operating Profit Margin at -171.42%, Pretax Profit Margin comes in at -97.22%, and Net Profit Margin reading is -96.85%. To continue investigating profitability, this company’s Return on Assets is posted at -1.41, Equity is 5.23 and Total Capital is -4.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.57 points at the first support level, and at 5.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.70, and for the 2nd resistance point, it is at 5.76.
Ratios To Look Out For
It’s worth pointing out that Serina Therapeutics Inc [AMEX:SER]’s Current Ratio is 2.24. Also, the Quick Ratio is 2.24, while the Cash Ratio stands at 1.7. Considering the valuation of this stock, the price to sales ratio is 444.69.
Transactions by insiders
Recent insider trading involved Moreadith Randall, Chief Scientific Officer, that happened on Aug 18 ’25 when 2227.0 shares were sold. Chief Scientific Officer, Moreadith Randall completed a deal on Aug 20 ’25 to sell 2077.0 shares. Meanwhile, Chief Scientific Officer Moreadith Randall sold 5500.0 shares on Aug 12 ’25.
